Desperate patients turn to ivermectin for long Covid; pharma lobbyists face their biggest test in a decade

The leaders of groups promoting ivermectin for long Covid have achieved large followings on social media through ties to right-wing organizations. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      Encouraged by right-wing doctor groups, desperate patients turn to ivermectin for long Covid By Olivia Goldhill Alfield Reeves for STAT ivermectin was initially promoted as a way to treat or prevent Covid infections. Now it's increasingly being marketed for long Covid. Read More STAT+: 'No magic bullet': For drugmakers and the FDA, clinical trials on ultra-rare diseases pose thorny challenges By Ed Silverman Meggan Haller for STAT The FDA's decision not to review an ultra-rare disease drug underscores the challenges in gathering and reviewing limited data. Read More STAT+: 'What can we do?': Pharma lobbyists face their biggest test in a decade, as Democrats barrel toward a vote on drug pricing By Rachel Cohrs Alex Hogan/STAT Pharma’s lobbyists are staring down their biggest test yet, as Democrats barrel toward a vote on drug pricing reform. Read More Sponsor content by PhRMA 340B is helping big hospitals & chain pharmacies The 340B program was designed to help patients. Instead, it has become less about patients and more about boosting the bottom lines of big hospitals and chain pharmacies. Large hospitals buy deeply discounted 340B medicines and then turn around and charge both uninsured patients and insurance companies higher prices, pocketing the difference with little to no evidence they use that money to help those who actually need it. Does that seem fair to patients? Learn more. STAT+: FDA agrees to review ALS treatment from Biogen, despite inconclusive clinical trial results By Adam Feuerstein Ruby Wallau for STAT The company had not previously disclosed the FDA submission, but waited for the agency to accept the filing before making an announcement. Read More What to know about polio, a disease once again vying for attention By Helen Branswell RIZWAN TABASSUM/AFP/Getty Images There have been recent signs that we may be forced to pay attention again to polio, a plague we thought was safely in the rear-view mirror. Read More STAT+: Despite their anger over high drug prices, Americans are giving pharma credit for helping contain Covid-19 By Nicholas Florko Matt Rourke/AP Nearly three quarters of Americans give the pharmaceutical industry credit for helping contain the Covid-19 pandemic. Read More Senators demand answers about federal prisons' scant use of Covid therapeutics By Nicholas Florko Erin Scott-Pool/Getty Images "The experience of the pandemic for the federally incarcerated population remains starkly worse than for non-incarcerated individuals." Read More Opinion: Value-based payment has produced little value. It needs a time-out By Kip Sullivan and Ana Malinow and Kay Tillow Adobe Billions of dollars have been spent on value-based payment programs that yielded little improvement in health or lower health care costs. Read More Tuesday, July 26, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser